Amendment 1 (9/11/2024): Adding Q&A as an attachment to the solicitation. See attached.
The Therapeutic Development Branch (TDB) in the intramural Division of Preclinical Innovation (DPI) at the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH) was established to enable preclinical development through collaborative partnerships. In alignment with accomplishing the Center’s mission, the Branch needs to conduct a portfolio impact analysis, from its inception in 2010 to present. The goal is to capture key metrics and evaluate the program’s research outcomes, including analyzing the economic and other quantitative and qualitative impact measures on further research and development and healthcare. TDB requires the expertise of a firm capable of conducting such types of specialized impact analyses of novel therapeutics and related technologies. The results of this analysis will be used by Branch leadership to inform future research policy and priorities.
See the attached Combined Synopsis/Solicitation, Statement of Work, and other attachments for complete requirement details.
